An interventional study of qSOFA, MEWS and physiological parameters combination in Sepsis, sponsored by St. Martin De Porress Hospital. Completed at 2 sites in Taiwan. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by St. Martin De Porress Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Sepsis with a site in Taiwan — 4 open to participants now, 5 under way, none of them phase 3. Sepsis · Taiwan.
Among the 51 studies in Sepsis with a site in Taiwan, this one is the 4th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 with no phase, and was the 45th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →4 of the 51 studies in Sepsis with a site in Taiwan are open now. Recruiting first, the newest first:
KK Women's and Children's Hospital · Sites in Taiwan, China, Hong Kong and 6 more countries
Ages up to 18
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18–100
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20–85
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 950 is above the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 151 across the 22 interventional studies, 200 across the 28 observational. Of the 26 that completed or were terminated, 5 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 51 have an industry lead sponsor. The 10 most frequent:
St. Martin De Porress Hospital is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
St. Martin De Porress Hospital has 1 study filed under Sepsis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 51 studies in Sepsis with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In the development of sepsis treatment of recent years, the demand for medical manpower has increased significantly when patients with sepsis appear because of the expansion of medical care demand and shortened response time related to sepsis Due to the shortage of manpower, a more simple and easy-to-operate inspection method is adopted and artificial intelligence technology is used to assist in the evaluation.
The applicability of physiological indicators MEWS, qSOFA and physiological parameters combination as sepsis screening tools in emergency department (ED) and predicting sepsis outcome in the emergency department. When patients with sepsis appear, artificial intelligence technology is used to remind the physicians to respond and administer drugs as soon as possible.
This is a single-center retrospective study of a group of patients admitted to the emergency department. The medical records were reviewed, mainly based on the hospital site records and the existing vital signs of the patients. Attended a hospital emergency room between January 2020 and December 2022. Physiological numerical indicators MEWS and qSOFA were all scored to understand the distribution of sepsis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Modified Early Warning Score(MEWS), quick Sequential Organ Failure Assessment(qSOFA) and physiological parameters combination are used in prediction of occurrence of sepsis
Other: qSOFA, MEWS and physiological parameters combination
qSOFA ,MEWS and physiological parameters combination used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
qSOFA used in emergency medicine department
The qSOFA score is a simple score consisting of three items: respiratory rate (RR) ≥ 22 breaths per minute, altered mentation (Glasgow Coma Scale \[GCS\] \< 15), and systolic blood pressure (SBP) \< 100 mmHg and lowest score is 1 and highest is 3. The more score will show more severe disease. MEWS score:Description Risk of death or ICU admission \<3: patient in a stable condition, 3-4: Signs of respiratory failure. Consider higher level of care, ≥5: Patient in a critical condition. Higher level of care recommended
Time frame: From date of randomization until the date of first documented progression assessed up to 36 months
Modified Early Warning Score(MEWS) which quickly determine whether a particular patient needs increased medical attention
MEWS score = Systolic blood pressure + Heart rate + Urine output + Respiratory rate + Temperature + AVPU. The lowest score is 0 and highest score is 14. The more score will show more severe disease. MEWS score:Description Risk of death or ICU admission \<3: patient in a stable condition, 3-4: Signs of respiratory failure. Consider higher level of care, ≥5: Patient in a critical condition. Higher level of care recommended
Time frame: From date of randomization until the date of first documented progression assessed up to 36 months
physiological parameters combination
Shock Index (SI) = Heart Rate / Systolic Blood Pressure Age-Adjusted Shock Index (Age SI) = Age x Shock Index Respiratory-Adjusted Shock Index (RASI) = HR/SBP × (RR/10)
Time frame: From date of randomization until the date of first documented progression assessed up to 36 months
Plan to share: No — The individual participant data (IPD) is not available to other researchers
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Jun 2023, 14 months.
Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 14 months is below that.
Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Martin De Porress Hospital